Alzheimer’s Therapeutics Market Size

Alzheimer’s Therapeutics Market Size

Alzheimer’s Therapeutics Market size was valued at USD 5.8 billion in 2023 and is expected to exhibit growth at a CAGR of 9.8% from 2024 to 2032. High market growth can be attributed to the ongoing advancements in diagnostic technologies, increasing prevalence of Alzheimer’s disease, expanding geriatric population, technological advancements in novel drug delivery system, and growing healthcare expenditure, among other contributing factors.

To get key market trends

  Download Free Sample

Moreover, the most significant driver is the rising prevalence of Alzheimer's disease globally. As the global population ages, the number of people diagnosed with Alzheimer’s disease continues to increase. For instance, according to Alzheimer's Association research published in 2023, an estimated 6.7 million Americans aged 65 and older had Alzheimer's disease, with the figure expected to rise to 13.8 million by 2060. Thus, the risk of Alzheimer’s increases with age, making it more common in the elderly population.
 

Furthermore, recent advancements in diagnostic technologies have made it easier to diagnose Alzheimer’s disease at an early stage. Improved imaging techniques, biomarkers, and genetic testing have contributed to early detection and intervention, which, in turn, drives the demand for therapeutics.
 

Alzheimer’s therapeutics refers to the range of treatments and interventions designed to manage, treat, and potentially cure Alzheimer's disease, encompassing pharmacological treatments like cholinesterase inhibitors and NMDA receptor antagonists, emerging therapies such as immunotherapies and gene therapies, as well as non-pharmacological interventions like cognitive and behavioral therapies, lifestyle modifications, and supportive care.